

American Journal of Urology Research

Case Report

Metachronism Association between Cervical and Kidney Cancer and the Importance of Follow-Up: A Case Report - 🗟

Mahmoud AlAfifi^{1*}, Yasmina Berrada², Clehaude Dibingue¹, Rida Hanane², Hassan Jouhadi², Amine Moataz¹, Mohammed Dakir¹, Adil Debbagh¹ and Rachid Aboutaieb¹

¹Department of Urology, CHU IBN ROCHD, Casablanca, Morocco ²Department of Radiotherapy and Oncology, CHU IBN ROCHD, Casablanca, Morocco

*Address for Correspondence: Mahmoud AlAfifi, Department of Urology, CHU IBN ROCHD, Casablanca, Morocco, Tel: +212- 700-14-8612; E-mail: dr.mahmoudalafifi1990@gmail.com

Submitted: 01 December 2021; Approved: 17 December 2021; Published: 18 December 2021

Cite this article: AlAfifi M, Berrada Y, Dibingue C, Hanane R, Jouhadi H, Moataz A, Dakir M, Debbagh A, Aboutaieb R. Metachronism Association between Cervical and Kidney Cancer and the Importance of Follow-Up: A Case Report. Am J Urol Res. 2021 Dec 18;6(1): 013-016.

Copyright: © 2021 AlAfifi M, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

The longer life expectancy of people treated for cancer has meant that the risk of finding a second primary cancer also increases over time.

The relationship between cervical cancer and kidney cancer remains poorly understood. Several factors have been reported in the literature including smoking and radiotherapy which are the most probable factors with the genetic factor that should be proven. The early detection and management of these second cancers would improve survival

This article takes up the observation of a woman treated for cervical cancer in 2016 by radiation and chemotherapy followed by surgery and who developed 5 years later hematuria associated with irritative urinary symptoms leading to the discovery of a kidney cancer treated by surgery alone.

INTRODUCTION

The kidney is considered a frequent site of second-time primary cancer. It's in general discovered fortuitously by radiographic imaging such as ultrasound, CT scan, or MRI, or after urinary symptoms.

We will present, in this article, the case of a woman treated and cured for cervical cancer who was diagnosed 5 later with a second renal cancer.

Our aim, firstly, is to emphasize the importance of a long-term follow-up for cancer patients, and secondly, to show that with current imaging techniques and therapies, the curative and radical treatment of 2 cancers can be possible.

OBSERVATION

Our Patient, B.F is 52 years old, without comorbidities, exposed to secondhand (passive) smoking, diagnosed with a localized squamous cell cervical carcinoma stage IIb (the kidney was free from any lesion at the moment of diagnosis) in 2016, treated by chemo-radiotherapy: 66 by including lumbar aortic lymph nodes + 6 cycles of cisplatin (brachytherapy source was over at this time) as a neoadjuvant treatment to a total hysterectomy (no residual tumor was detected in pathology examination) then she was followed in consultation every 3 to 6 months.

Mrs. B.F presented in January 2021 with intermittent non-clotting hematuria accompanied by irritative urinary symptoms without low back pain.

The clinical examination found a patient with good performance status, without any remarkable sign, as well as a normal vaginal examination.

The reno-abdominal ultrasonography of the patient revealed a right renal process and the uroscanner concluded to a right renal mass in its superior pole, iso-dense and heterogeneously enhanced measuring 31 x 32 x 36 mm, arriving at contact with the superior calyx and bulging in its lumen (which creates confusion between its renal or upper urinary tracts 'origin) (Figure 1).

There was no sign of recurrence in hysterectomy bed.

Her chest CT scan was normal, and since a tumor in the upper urinary tracts was suspected, her right ureteroscopy revealed petechial images of the right ureter and the pyelo-caliceal cavities (Figure 2) with negative selective urinary cytology.

Our patient was programmed after a multidisciplinary meeting for right partial nephrectomy, but we encountered an intraoperative difficulty which changed our attitude towards a right total nephrectomy (Figure 3).



Figure 1: Coronal section of uroscanner showing right renal mass.



Figure 2: Endoscopic appearance of petechial lesions of the right ureter.



Figure 3: Right nephrectomy surgical specimen.

American Journal of Urology Research

The postoperative follow-up was good. The pathologic examination concluded a clear cell renal carcinoma ISUP 2 pT1aN0M0

We still see our patient in medical consultation and until today her check-up is normal.

DISCUSSION

A second primary cancer is defined according to the established SEER criteria and previous studies, as two tumors arising in different sites, or at the same site with different histology [1].

Their incidence remains low, around 16% or less, with a time to onset varying from 5 to 10 years from the initial tumor [2].

The most common effective causes are late toxic effects of chemotherapy, radiotherapy, hormone therapy, prolonged survival through treatment of primary cancer, genetic factors, lifestyle, and prolonged exposure to certain carcinogens including tobacco [1,2].

On one hand, previous research suggests a joint effect of tobacco carcinogens leading to DNA damage and decreased immune clearance of HPV causing malignancy and hence cervical cancer.

However, the relationship between cervical cancer and renal cancer is not well elucidated in the literature and several hypotheses have been proposed.

On the other hand, smoking, both active and passive, is also considered by several authors as a risk factor for the occurrence of kidney cancer, which may explain the synchronous or metachronous existence of these two cancers in the same person.

We should highlight that the kidney is, in general, a frequent site of second primary cancer after lung and uterus². It also occurs, most often after colorectal cancer, bronchopulmonary cancer in a primary cervical cancer [1].

In a study done by Kleinermen [3], with the participation of 8 European centers, in the purpose of evaluating the occurrence of secondary cancers during the surveillance of cervical cancer, the results showed that the highly irradiated sites (doses organs> 3 Gy) had a higher incidence of cancer after 30 years or more from radiation therapy. These sites were primarily the bladder, rectum, vagina, vulva, and ovary.

However, among the organs receiving between 1 and 3 Gy, only the risk of kidney cancer was significantly elevated in patients irradiated after 30 years and this increases over time.

They also support the hypothesis according to which the occurrence of kidney cancer after cervical cancer may be mainly due to two factors: radiotherapy and tobacco.

Similar results have been published by Evans concerning the frequent sites of second cancer after cervical cancer as well as the role of radiotherapy and tobacco in the occurrence of kidney cancer as secondary cancer.

Taking into consideration that the usual type of radiationinduced cancer is sarcoma and that our patient had her kidney cancer just 5 years after radiation therapy, Can we say that the kidney cancer is radiation-induced?

Our patient's ureteroscopy had shown petechial lesions in the right ureter and pyelo-caliceal cavities.

Knowing that the most frequent urological complications [4] after radiotherapy for cervical cancer are: ureteral obstruction, radio cystitis, and vesicovaginal fistula, these lesions can be attributed to radiotherapy and we, therefore, emphasize the crucial importance of long-term follow-up to watch out for short-term and long-term complications of radiotherapy.

Our patient received concomitant cisplatin. Although the great benefits of this drug in healing several cancers, it's well known for its important nephrotoxicity. According to a Sandhya Manohar, et al. [5] review, the most important side effect of cisplatin is acute and chronic renal failure, but no author or study has yet proven its role in secondary renal cancer.

Finally, several studies have tried to prove the genetical relationship between different solid tumors and in particular between the kidney and the cervix tumor such as the loss of expression of the FHIT tumor suppressor gene in chromosome 3p [6] or the substantial increase expression of NETO2 gene [7] which is found frequently in renal cancer and to a lesser extent in cervical carcinoma.

Other epigenetic abnormalities such as methylation of the LRRC3B [8] gene have also been described.

CONCLUSION

As well as scientific advances in diagnosis and treatment of cancers continue to emerge, vigilant surveillance and screening for cancer survivors are essential to reduce mortality and morbidity and especially to detect second cancers at an early stage to be curative and extend their life expectancy.

REFERENCES

- Adjei Boakye E, Wang M, Sharma A, Jenkins WD, Osazuwa-Peters N, Chen B, Lee M, Schootman M. Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers. J Cancer Res Clin Oncol. 2020 Jul;146(7):1765-1779. doi: 10.1007/s00432-020-03232-8. Epub 2020 Apr 30. PMID: 32356175.
- Seegobin K, Staggs E, Khawaja R, Maharaj S, Gautam S, Smotherman C, Rana F. Pilot study on the occurrence of multiple cancers following cancerrelated therapy at the University of Florida, Jacksonville (2011-2016). J Investig Med. 2018 Oct;66(7):1050-1054. doi: 10.1136/jim-2018-000772. Epub 2018 Jun 6. PMID: 29880535.
- Kleinerman RA, Boice JD Jr, Storm HH, Sparen P, Andersen A, Pukkala E, Lynch CF, Hankey BF, Flannery JT. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer. 1995 Aug 1;76(3):442-52. doi: 10.1002/1097-0142(19950801)76:3<442::aidcncr2820760315>3.0.co;2-l. PMID: 8625126.
- Li F, Guo H, Qiu H, Liu S, Wang K, Yang C, Tang C, Zheng Q, Hou Y. Urological complications after radical hysterectomy with postoperative radiotherapy and radiotherapy alone for cervical cancer. Medicine (Baltimore). 2018 Mar;97(13):e0173. doi: 10.1097/MD.00000000010173. PMID: 29595646; PMCID: PMC5895433.
- Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018 Feb;31(1):15-25. doi: 10.1007/s40620-017-0392-z. Epub 2017 Apr 5. PMID: 28382507.
- Hallas C, Albitar M, Letofsky J, Keating MJ, Huebner K, Croce CM. Loss of FHIT expression in acute lymphoblastic leukemia. Clin Cancer Res. 1999 Sep;5(9):2409-14. PMID: 10499611.
- Oparina Nlu, Sadritdinova AF, Snezhkina AV, Dmitriev AA, Krasnov GS, Senchenko VN, Mel'nikova NV, Belenikin MS, Lakunina VA, Veselovskii VA, Stepanov OA, Kudriavtseva AV. [Increase in NETO2 gene expression is a potential molecular genetic marker in renal and lung cancers]. Genetika. 2012 May;48(5):599-607. Russian. PMID: 22830255.



 Haraldson K, Kashuba VI, Dmitriev AA, Senchenko VN, Kudryavtseva AV, Pavlova TV, Braga EA, Pronina IV, Kondratov AG, Rynditch AV, Lerman MI, Zabarovsky ER. LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication. Biochimie. 2012 May;94(5):1151-7. doi: 10.1016/j.biochi.2012.01.019. Epub 2012 Feb 2. PMID: 22321817.